Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Balversa (erdafitinib) for the Treatment of Urothelial Carcinoma

Drug Name

Balversa™ (erdafitinib)

Developers

Janssen Pharmaceutical and Astex Pharmaceuticals

Therapy Class

Kinase inhibitor

Product Description

Oral FGFR kinase inhibitor

Current Indication

Urothelial carcinoma

Market Sector

Oncology

Development Status

Approved in the US
Expand
Close
Close
Close

Go Top